Acorah Software Products - Accounts Production 15.0.400 true true 31 December 2022 1 May 2022 false true No description of principal activity 1 January 2023 31 December 2023 31 December 2023 06576819 Mr Howard Shapland John Bryer Mr Howard Shapland iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 06576819 2022-12-31 06576819 2023-12-31 06576819 2023-01-01 2023-12-31 06576819 frs-bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 06576819 frs-bus:FilletedAccounts 2023-01-01 2023-12-31 06576819 frs-bus:Micro-entities 2023-01-01 2023-12-31 06576819 frs-bus:EntityHasNeverTraded 2023-01-01 2023-12-31 06576819 frs-bus:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 06576819 frs-bus:Director1 2023-01-01 2023-12-31 06576819 frs-bus:Director2 2023-01-01 2023-12-31 06576819 frs-bus:CompanySecretary1 2023-01-01 2023-12-31 06576819 2022-04-30 06576819 2022-12-31
Registered number: 06576819
Biovista Sciences Limited
Unaudited Financial Statements
For The Year Ended 31 December 2023
GLX Accounting Limited
ICAEW Chartered Accountants
69-75 Thorpe Road
Norwich
NR1 1UA
Balance Sheet
Registered number: 06576819
31 December 2023 31 December 2022
£ £
Current assets 100 100
NET CURRENT ASSETS 100 100
TOTAL ASSETS LESS CURRENT LIABILITIES 100 100
NET ASSETS 100 100
CAPITAL AND RESERVES 100 100

Notes

1. General Information
Biovista Sciences Limited is a private company, limited by shares, incorporated in England & Wales, registered number 06576819 . The registered office is C/o GLX, 69-75 Thorpe Road, Norwich, NR1 1UA.
For the year ending 31 December 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
On behalf of the board
Mr Howard Shapland
Director
5th August 2024